Europe represents the second-largest market in the Hyperbaric Oxygen Therapy Market , valued at USD 350 million in 2024 and holding a 27.38% global share. The region's growth is driven by rising incidences of chronic diseases, increasing awareness of HBOT benefits, and expanding applications in sports medicine and rehabilitation. The European market is characterized by advanced healthcare infrastructure, strong regulatory frameworks, and a growing network of hyperbaric facilities.

The European Medicines Agency (EMA) and national regulatory bodies have established guidelines for HBOT, ensuring safety and efficacy standards. The European Centre for Disease Prevention and Control reports increasing adoption of advanced medical technologies across healthcare systems, improving treatment outcomes. The region's focus on evidence-based medicine and patient-centered care supports the integration of HBOT into clinical practice.

Germany is a key contributor, with a 29% share valued at USD 101.42 million, driven by strong healthcare systems and a robust medical technology manufacturing sector. The country's aging population and high prevalence of chronic diseases create sustained demand for hyperbaric therapies. The United Kingdom holds a 21% share valued at USD 73.42 million, supported by increasing adoption of advanced therapies and a growing network of HBOT centers. The National Health Service's focus on wound care and rehabilitation services drives demand.

The competitive landscape in Europe features a mix of established global players and specialized regional companies. Haux-Life-Support (DE) and Boccard (FR) are prominent players, focusing on technological advancements and patient-centric solutions. The region is also seeing growth in hyperbaric applications for sports medicine, with athletes increasingly using HBOT for recovery and performance enhancement. The presence of major sporting events and training centers across Europe supports this trend. As awareness of HBOT benefits continues to grow and clinical evidence expands, the European market is expected to maintain steady expansion, driven by innovation, regulatory support, and a strong commitment to patient-centered care.